Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck And Cardiome Obtain EU Approval For Vernakalant In Atrial Fibrillation

This article was originally published in The Pink Sheet Daily

Executive Summary

First of several anticipated approvals for the AF drug nets Cardiome a $30 million milestone payment from Merck.

You may also be interested in...



Merck Drops Development Of Cardiome’s Oral Vernakalant

Higher regulatory hurdles for anti-arrhythmic drugs have pushed Merck to discontinue the development of Cardiome’s oral vernakalant.

Xention Siphons Off OAB Therapy Into New Spin Out, Provesica

Atrial fibrillation will be Xention's focus following the spin-out of its overactive bladder assets into a new company, Provesica

Xention Siphons Off OAB Therapy Into New Spin Out, Provesica

Atrial fibrillation will be Xention's focus following the spin-out of its overactive bladder assets into a new company, Provesica

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel